Sporadic porphyria cutanea tarda: treatment with chloroquine decreases hyperglycemia and reduces development of metabolic syndrome

Eur J Intern Med. 2014 Jul;25(6):e76-7. doi: 10.1016/j.ejim.2014.02.009. Epub 2014 Mar 12.

Authors

Aurora González-Estrada¹, Luis Bonifacio Gomez-Morales², Alexei Gonzalez-Estrada³, Jose Salvador García-Morillo²

Affiliations

¹ Department of Internal Medicine, Collagen and Minoritarian Diseases, Virgen del Rocio Hospital, Seville, Spain. Electronic address: [email protected].
² Department of Internal Medicine, Collagen and Minoritarian Diseases, Virgen del Rocio Hospital, Seville, Spain.
³ Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.

PMID: 24630799
DOI: 10.1016/j.ejim.2014.02.009

No abstract available

Keywords: Chloroquine; Metabolic syndrome; Porphyria cutanea tarda; Transferrin.

Publication types

Letter

MeSH terms

Adolescent
Adult
Chloroquine / therapeutic use*
Cohort Studies
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / etiology
Female
Glycated Hemoglobin
Humans
Hyperglycemia / drug therapy
Hyperglycemia / etiology
Iron Overload / blood
Male
Metabolic Syndrome / etiology
Metabolic Syndrome / prevention & control*
Middle Aged
Phlebotomy
Porphyria Cutanea Tarda / complications
Porphyria Cutanea Tarda / drug therapy*
Transferrin
Treatment Outcome

Substances

Glycated Hemoglobin A
Transferrin
hemoglobin A1c protein, human
Chloroquine